Integrum granted US patent for attachment device allowing natural wrist rotation for bone-anchored prostheses
Integrum, a recognized global leader in bone-anchored prostheses, has been granted a patent by the US Patent and Trademark Office for an attachment device that allows natural wrist rotation for bone-anchored prostheses.
Integrum has been granted a patent by the US Patent and Trademark Office for an attachment device that allows natural wrist rotation for bone-anchored prostheses.
Upper extremity amputees with an amputation below the elbow (also known as trans-radial amputation patients) who opt for bone-anchored prostheses solutions, have two implants placed in the residual limb. One implant is inserted into the radius and one implant into the ulna.
At this amputation level, bone-anchored prostheses have the potential to preserve the natural range of wrist motion and rotation. This is possible by enabling the radius and the ulna to move with respect to each other, whereas socket-suspended prostheses generally lock the forearm bones in one position. In this way, the bone-anchored prosthesis with the patented attachment device restores the full functionality of the original wrist joint.
The patented attachment device enables the safe and reliable connection to a commercial prosthesis, while supporting the complex dynamics of wrist rotation. Not only does this improve the performance of activities of daily living, but it also reduces compensatory shoulder movements that can lead to secondary health problems over time.
For further information, please contact:
Maria Lopez, CEO
Cell. 0708-46 10 69
Email: maria.lopez@integrum.se
Certified Adviser:
Erik Penser Bank AB
Tel. +46 8 463 8000
Email: certifiedadviser@penser.se
About Integrum
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990, the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 14 countries has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for bone anchored prosthetics available in the U.S. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.
Tags:
